Theralizumab | TGN1412 | TAB-08 | TABO8

Size	Availability	Price(USD)	VIP Price (USD)	Quantity
1 mg	3-5days	￥3236.00	Visible after login	- +
5 mg	3-5days	￥8480.00	Visible after login	- +

Size

Availability

Price(USD)

VIP Price (USD)

Quantity

1 mg

3-5days

￥3236.00

Visible after login

- +

5 mg

3-5days

￥8480.00

Visible after login

- +

Product Overview

Product Name	Theralizumab \| TGN1412 \| TAB-08 \| TABO8
CAS	906068-56-2
Storage condition	store at -20°C \| Shipping with blue ice.

Product details

Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis.

Related literature

From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis.

PMID: 27586803

The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account.

PMID: 27191544 DOI: 10.1111/febs.13754

Sorry, no related items

History

Theralizumab | TGN1412 | TAB-08 | TABO8

DPCPX (Synonyms: PD 116948)

102146-07-6 98+%

HL1927

5-Hydroxymethylfurfural (HMF)

67-47-0 98+%

HL1785

Sinapaldehyde glucoside

154461-65-1 98+%

HL1720

Secoxyloganin methyl ester

74713-15-8 98+%

HL1015

Vinburnine Base (Synonyms: (-)-Eburnamonine; (-)-Vincamone; Vinburnine; L-Eburnamonine)

4880-88-0 Purity: 99.28%

SNX 2112 | PF-04928473

908112-43-6 98+%

西拉利珠单抗

Chemical safety data sheet(MSDS)